The Cancer

Don't Miss

How Caregivers Can Assist Liked Ones With Lung Most cancers Really feel in Management

Chris Draft mentioned sufferers with lung most cancers and their caregivers can regain management after analysis by displaying up, staying knowledgeable and leaning into advocacy,...

Household Begins AYA Most cancers Basis After Lymphoma Prognosis

Elaine Riozzi Bodine and her daughter Alayna turned a life-altering analysis right into a mission to help different adolescents and younger adults with most cancers....

Childhood Most cancers Survivors Face Lengthy-Time period Meningioma Danger

Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...

Vital Information

Facts

Latest Articles

Remedy Discontinuations Diminished With Jaypirca in CLL, SLL

Remedy with Jaypirca was proven to cut back therapy discontinuations in sufferers with CLL or SLL. Amongst sufferers with beforehand handled persistent lymphocytic...

Enhertu Improves Development-Free Survival in HR+, HER2-Low/Ultralow Metastatic Breast Most cancers

Enhertu confirmed improved progression-free survival in contrast with doctor's alternative of remedy in sure sufferers with metastatic breast most cancers. Sufferers with hormone...

Imlunestrant-Primarily based Remedy Could Enhance Survival With out Development in Superior Breast Most cancers

Remedy with imlunestrant improved PFS for sufferers with ER-positive, HER2-negative advance breast most cancers with ESR1 mutations in contrast with hormone remedy. The...

Native Recurrence Lowered With Rapid Surgical procedure in Aged Sufferers With Breast Most cancers

Rapid surgical procedure for aged sufferers with breast most cancers lowered native recurrence charges in comparison with delayed surgical procedure.In aged sufferers with...

Lynparza Continues to Profit in BRCA1/2+, HER2- Breast Most cancers

Adjuvant Lynparza advantages sufferers with BRCA1/2 mutation-positive, HER2-negative breast most cancers, six-year OlympiA trial knowledge present.Sufferers with BRCA1/2 mutation-positive, HER2-negative high-risk breast most...

Hot Topics